Print

PamGene Enhances Drug Development Testing Platform With Questra Device Management Software 
10/19/2005 5:10:08 PM

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Feb. 24, 2004--The Dutch-based biotechnology company PamGene International B.V. is integrating Questra intelligent device management (IDM) software into an advanced microarray testing platform PamGene is designing for the drug development market.

PamStation®96, a fully automatic 96-array platform for high-throughput applications in drug development, will be equipped with Questra IDM software that monitors the device's operations and performance. If the tests or the instrument needs attention, the appropriate service staff can be alerted automatically over the Internet or via cell phone or pager. Remote monitoring and management delivers the high uptime and fast service response that is a strong competitive advantage for complex devices located in pharmaceutical research facilities around the world.

Questra is a leader in IDM software whose customers are well known in such diverse market segments as medical device, life science, and power industries. Companies such as GE Health Care, Diagnostic Products Corp., Eaton Corp.'s Cutler-Hammer business, Swissray International, and eBidenergy use Questra IDM software to send data from remote devices over the Internet to cell phones and pagers, call centers, and field service operations centers. Using this real-time data improves cost effectiveness and enhances service and support options.

Tim Kievits, CEO of PamGene, said, "The PamStation96 will strongly enhance the data-to-knowledge process during drug screening and validation as well as reduce the drug testing time by monitoring many variables at once. This enables drug developers to perform more efficient research and a faster time to market. Questra software is an important element in keeping the platform available and hence, the cost of drug discovery down."

In July PamGene raised EUR 10 million in a second financing round. Lead investor LCF Rothschild Venture Partners (France) joined existing venture capital investors Alta Partners (USA), GIMV (Belgium) and Life Sciences Partners (the Netherlands) in this round.

"PamGene is about removing constraints on assay performance," said Jim Gagnard, Questra president and CEO. "As part of that effort, Questra software will make sure that device performance and downtime issues are no longer constraints for drug development companies, who need to speed their time to market with new discoveries."

About PamGene (www.pamgene.com)

Based on its 5D-Pulse(TM) Technology, PamGene adds value to the pharmaceutical development process as the leading provider of complete microarray-based solutions. PamGene is a post-genomics international biotechnology company that owns patented technologies for second-generation microarray products including an innovative transcription profiling system. PamGene specifies its technology and products for use in pharma-biotech R&D and production, academic research, non-pharma life sciences, and health management testing applications through the formation of bespoke partnerships. PamGene has a partnership with Olympus Optical Co Ltd. PamGene is based in 's-Hertogenbosch in The Netherlands.

About Questra (www.questra.com)

Questra Corporation is an enterprise software company leading the development of intelligent device management solutions. The company's remote diagnostic and monitoring applications collect data from medical instruments, printing equipment, power monitors, and other remote devices. Equipment manufacturers and their customers using the Questra Smart Service Solution lower their service costs through reduced emergency calls, proactive device monitoring and diagnostics, and streamlined accounting for consumables and usage. Questra is headquartered in Redwood City, CA.

Contact:

Questra Leslie Schroeder, 415-999-1394 leslie@schroederpr.com or PamGene Saskia Goutziers, +31 73 6158080 sgoutziers@pamgene.com

Source: Questra Corporation


//-->